http://www.mmm-online.com Latest articles from Medical Marketing and Media Features MMM Features Features mmmsubs@haymarketmedia.com no What's that image fading from view? Pharma just sped by one precipice, losing $30 billion in brand revenue to the patent cliff. But another scary patent peak lies ahead. Marc Iskowitz reports http://www.mmm-online.com/2013-pharma-report-dont-look-back/article/290191/ Thu, 02 May 2013 04:00:00 GMT What's that image fading from view? Pharma just sped by one precipice, losing $30 billion in brand revenue to the patent cliff. But another scary patent peak lies ahead. Marc Iskowitz reports MMM Co-pay cards and loyalty/CRM programs are a hot topic. As Larry Dobrow finds, a big disconnect still divides the stakeholders in this field http://www.mmm-online.com/co-payloyalty-programs-shuffling-the-pack/article/290289/ Wed, 01 May 2013 04:00:00 GMT Co-pay cards and loyalty/CRM programs are a hot topic. As Larry Dobrow finds, a big disconnect still divides the stakeholders in this field MMM Mike Kaufman, Executive sponsor, Women's Initiative Network, Cardinal Health http://www.mmm-online.com/headliner-mike-kaufmann-cardinal-health/article/290371/ Wed, 01 May 2013 04:00:00 GMT Mike Kaufman, Executive sponsor, Women's Initiative Network, Cardinal Health MMM The 2013 panel features a variety of esteemed leaders, thinkers and experts representing a range of disciplines. Their hard work will determine which agencies win gold on October 2 in New York. http://www.mmm-online.com/mmm-awards-2013-judging-panel/article/290307/ Wed, 01 May 2013 04:00:00 GMT The 2013 panel features a variety of esteemed leaders, thinkers and experts representing a range of disciplines. Their hard work will determine which agencies win gold on October 2 in New York. MMM Noah Pines on the roll-out of Pfizer's new RA pill Xeljanz, a biologic maker's response, and how the upstart may prompt a move away from needle-based therapies http://www.mmm-online.com/therapeutic-focus-2013-rheumatology/article/290301/ Wed, 01 May 2013 04:00:00 GMT Noah Pines on the roll-out of Pfizer's new RA pill Xeljanz, a biologic maker's response, and how the upstart may prompt a move away from needle-based therapies MMM When it comes to conveying the changes that have transformed pharma, college degree programs can fall short. The answer may be faculty with pharma marketing experience, writes Joe Dysart http://www.mmm-online.com/training-education-majoring-in-change/article/290299/ Wed, 01 May 2013 04:00:00 GMT When it comes to conveying the changes that have transformed pharma, college degree programs can fall short. The answer may be faculty with pharma marketing experience, writes Joe Dysart MMM Social, mobile or cloud-based technologies may take some getting used to for clinical investigators. But the need to trim the time and cost of R&D may make them worth a closer look. Joe Dysart reports http://www.mmm-online.com/clinical-research-trials-tribulations/article/286653/ Mon, 01 Apr 2013 04:00:00 GMT Social, mobile or cloud-based technologies may take some getting used to for clinical investigators. But the need to trim the time and cost of R&D may make them worth a closer look. Joe Dysart reports MMM Consumer ad spend plunged in 2012, as the ranks of mass-market blockbusters thinned and marketers turned from TV toward digital. But the DTC debate rages on, even as evidence of its merits mounts http://www.mmm-online.com/direct-to-consumer-report-dtc-drain/article/285718/ Mon, 01 Apr 2013 04:00:00 GMT Consumer ad spend plunged in 2012, as the ranks of mass-market blockbusters thinned and marketers turned from TV toward digital. But the DTC debate rages on, even as evidence of its merits mounts MMM Kevin Rigby, VP/US country head of public affairs, Novartis Pharmaceuticals http://www.mmm-online.com/headliner-kevin-rigby-novartis-pharmaceuticals/article/286658/ Mon, 01 Apr 2013 04:00:00 GMT Kevin Rigby, VP/US country head of public affairs, Novartis Pharmaceuticals MMM The days of 350-million-dollar TV spending may be gone, but top DTC campaigns must still be tied to unique insights. And, as Deborah Dick-Rath finds, the best are. Here's her top 10 http://www.mmm-online.com/mmms-best-dtc-ads-ever/article/286642/ Mon, 01 Apr 2013 04:00:00 GMT The days of 350-million-dollar TV spending may be gone, but top DTC campaigns must still be tied to unique insights. And, as Deborah Dick-Rath finds, the best are. Here's her top 10 MMM With two drugs for one ultra-orphan disease—Kynamro and Juxtapid—getting FDA's nod a month apart, intense competition is in the cards. Tanya Lewis looks at their commercial launches http://www.mmm-online.com/orphan-diseases-rare-rivalry/article/286654/ Mon, 01 Apr 2013 04:00:00 GMT With two drugs for one ultra-orphan disease—Kynamro and Juxtapid—getting FDA's nod a month apart, intense competition is in the cards. Tanya Lewis looks at their commercial launches MMM As specialty drugs enter the respiratory market, alongside successors to current blockbusters, Noah Pines looks at how big pharma aspires to sustain sales, and how the new entrants are making inroads http://www.mmm-online.com/therapeutic-focus-2013-respiratory/article/286649/ Mon, 01 Apr 2013 04:00:00 GMT As specialty drugs enter the respiratory market, alongside successors to current blockbusters, Noah Pines looks at how big pharma aspires to sustain sales, and how the new entrants are making inroads MMM Patent clocks are ticking on branded biologics worth billions. As time runs out, it's not clear when look-alikes will arrive in the US or be adopted, Deborah Weinstein reports http://www.mmm-online.com/biosimilars-on-pins-and-needles/article/281500/ Fri, 01 Mar 2013 05:00:00 GMT Patent clocks are ticking on branded biologics worth billions. As time runs out, it's not clear when look-alikes will arrive in the US or be adopted, Deborah Weinstein reports MMM Meeting pharma's value-based reimbursement challenge: Marc Iskowitz looks at how companies, driven by payer and provider pressure, are leveraging Big Data across the product lifecycle http://www.mmm-online.com/data-analytics-deep-is-the-new-big/article/281386/ Fri, 01 Mar 2013 05:00:00 GMT Meeting pharma's value-based reimbursement challenge: Marc Iskowitz looks at how companies, driven by payer and provider pressure, are leveraging Big Data across the product lifecycle MMM Mike Cunnion, CEO, Remedy Health Media http://www.mmm-online.com/headliner-portal-chief-remodels-web-content/article/281608/ Fri, 01 Mar 2013 05:00:00 GMT Mike Cunnion, CEO, Remedy Health Media MMM Pharma's turn to specialty drugs hasn't been good for print. Ad pages in medical/surgical journals fell steeply in 2012, despite the pickup in FDA approvals. Larry Dobrow reports the full-year numbers http://www.mmm-online.com/journal-ad-report-2012-in-a-bind/article/281402/ Fri, 01 Mar 2013 05:00:00 GMT Pharma's turn to specialty drugs hasn't been good for print. Ad pages in medical/surgical journals fell steeply in 2012, despite the pickup in FDA approvals. Larry Dobrow reports the full-year numbers MMM The industry turned out in droves to honor three luminaries and the 2013 'Future Famers' at the Medical Advertising Hall of Fame induction dinner on February 5 http://www.mmm-online.com/mahf-2013-honors-class/article/281590/ Fri, 01 Mar 2013 05:00:00 GMT The industry turned out in droves to honor three luminaries and the 2013 'Future Famers' at the Medical Advertising Hall of Fame induction dinner on February 5 MMM The prevalence of diabetes and obesity is still high, despite piecemeal attempts at treating them. Among drug makers' latest efforts: pills that address both at once. Noah Pines reports http://www.mmm-online.com/therapeutic-focus-2013-metabolic/article/281508/ Fri, 01 Mar 2013 05:00:00 GMT The prevalence of diabetes and obesity is still high, despite piecemeal attempts at treating them. Among drug makers' latest efforts: pills that address both at once. Noah Pines reports MMM Ryan Cohlhepp—Senior Director, Head of US Marketing, Millennium: The Takeda Oncology Company http://www.mmm-online.com/headliner-millennium-marketer-sprints-ahead/article/277483/ Fri, 01 Feb 2013 05:00:00 GMT Ryan Cohlhepp—Senior Director, Head of US Marketing, Millennium: The Takeda Oncology Company MMM With more sources of medical info than ever—both in print and online—many doctors are making the decision to unplug from pharma. How to reach them in the age of digital media http://www.mmm-online.com/non-personal-promotion-digital-to-docs/article/277479/ Fri, 01 Feb 2013 05:00:00 GMT With more sources of medical info than ever—both in print and online—many doctors are making the decision to unplug from pharma. How to reach them in the age of digital media MMM